Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US74587B1017
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00BRBHVD0
PLSE
Pulse Biosciences Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $PLNG
NAME
Pulse Biosciences Inc
ISIN
US74587B1017
TICKER
PLSE
MIC
XNAS
REUTERS
PLSE.OQ
BLOOMBERG
PLSE US
Tue, 04.03.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to 14 new employees as equity inducement awards outside of the Company's 2017 Equity Inc...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming TD Cowen 45th Annual Health Care Conference in Boston. Pulse Biosciences’ Management is scheduled to present on Wednesday, March 5, 2025, at 10:...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. “I am excited to announce Jon as our next CFO...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.01.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its nanosecond PFA Percutaneous Electrode System will be featured in a clinical science session and a video session at the North American Society for Interventional Thy...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.01.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting....
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.01.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. "We are thrilled to have Paul assume...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.01.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Pulse Biosciences’ Management is scheduled to present on Wednesday, January 15,...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.12.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if t...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.12.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company’s Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 17.12.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the nano-PFA Cardiac Surgical System over radiofrequ...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.10.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia pres...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Pl...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Red...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.10.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.08.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.08.2024       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.05.2024       Pulse Biosciences
US74587B1017

Das Instrument 6L8 US74587B1017 PULSE BIOSCIENCES DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2024 und ex Kapitalmassnahme am 30.05.2024 The instrument 6L8 US74587B1017 PULSE BIOSCIENCES DL-,001 EQUITY is traded cum capital adjustment on 29.05.2024 and ex capital adjustment on 30.05.2024...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 18, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Pulse securities between Jan...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 18.04.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - April 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.04.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - April 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.04.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - April 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.04.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - April 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sun, 10.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sat, 09.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certai...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sun, 03.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certai...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.04.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 30, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sun, 27.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 26, 2022) - WHY: New York, N.Y., March 26, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff d...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 24, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 23, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certa...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 22, 2022) - WHY: New York, N.Y., March 22, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff d...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sat, 19.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 17, 2022) - WHY: New York, N.Y., March 17, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff d...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 14, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certa...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 14, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sat, 12.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 12, 2022) - WHY: New York, N.Y., March 12, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff d...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 10, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certa...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink